Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CPT2 | P23786 | 1/20 | 0.43 |
| ▸ | CPT1A | P50416 | 1/20 | 0.43 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632926 | 0.87 | HCAR3 (0.46) | HCAR3KDM4EHPGDALDH1A1SLC22A12 | |
| SCHEMBL30987624 | 0.83 | MAPT (0.44) | KDM4EHPGDALDH1A1 | |
| SCHEMBL20604896 | 0.83 | MAPT (0.44) | KDM4EHPGDALDH1A1 | |
| SCHEMBL23535727 | 0.82 | HCAR3 (0.55) | HCAR3KDM4EHPGDALDH1A1CPT2 | |
| SCHEMBL30040739 | 0.82 | HCAR3 (0.55) | HCAR3KDM4EHPGDALDH1A1CPT2 | |
| SCHEMBL25113848 | 0.81 | HCAR3 (0.50) | HCAR3KDM4EHPGDALDH1A1CPT2 | |
| SCHEMBL30189248 | 0.81 | HCAR3 (0.50) | HCAR3KDM4EHPGDALDH1A1CPT2 | |
| SCHEMBL23559718 | 0.81 | HCAR3 (0.50) | HCAR3KDM4EHPGDALDH1A1CPT2 | |
| SCHEMBL29960281 | 0.81 | HCAR3 (0.50) | HCAR3KDM4EHPGDALDH1A1CPT2 | |
| SCHEMBL29301488 | 0.81 | HCAR3 (0.50) | HCAR3KDM4EHPGDALDH1A1CPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999957-B2 | Heterocyclic compounds as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MERCK SHARP & DOHME LLC | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096084-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS | MAPK1, MAPK6, MAPK3 | HCAR3 814/4885KDM4E 1557/4885HPGD 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.